Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | APLNR | P35414 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9985197 | 1.00 | L3MBTL1 (0.44) | L3MBTL1DRD2APLNRALDH1A1HTT | |
| SCHEMBL24423760 | 0.79 | DRD2 (0.47) | L3MBTL1DRD2APLNRALDH1A1HTT | |
| SCHEMBL384229 | 0.78 | YTHDC1 (0.55) | ALDH1A1MEN1KMT2A | |
| SCHEMBL23329339 | 0.78 | YTHDC1 (0.55) | ALDH1A1MEN1KMT2A | |
| SCHEMBL384230 | 0.78 | YTHDC1 (0.55) | ALDH1A1MEN1KMT2A | |
| SCHEMBL20871846 | 0.77 | CNR1 (0.52) | DRD2APLNRMEN1KMT2AEPHX2 | |
| SCHEMBL22340865 | 0.77 | LTA4H (0.49) | DRD2SMN1; SMN2MEN1KMT2AEPHX2 | |
| SCHEMBL16231832 | 0.77 | DAO (0.41) | L3MBTL1ALDH1A1SMN1; SMN2HTR2AMEN1 | |
| SCHEMBL23951718 | 0.76 | SLC6A2 (0.53) | L3MBTL1DRD2APLNRALDH1A1SMN1; SMN2 | |
| SCHEMBL3692058 | 0.75 | KMT2A (0.58) | ALDH1A1SMN1; SMN2KMT2ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160280703-A1 | Heteroaryloxycarbocyclyl Compounds as PDE 10 Inhibitors | AMGEN INC. | 2016-09-29 | — | — | US | disclosed |
| US-8952037-B2 | Heteroaryloxycarbocyclyl compounds as PDE10 inhibitors | AMGEN INC. (US) | 2015-02-10 | — | — | US | disclosed |
| EP-2569306-A1 | HETEROARYLOXYCARBOCYCLYL COMPOUNDS AS PDE10 INHIBITORS | Amgen Inc. (US) | 2013-03-20 | — | — | EP | disclosed |
| US-20110306591-A1 | HETEROARYLOXYCARBOCYCLYL COMPOUNDS AS PDE10 INHIBITORS | INC., AMGEN | 2011-12-15 | — | — | US | disclosed |
| WO-2011143366-A1 | HETEROARYLOXYCARBOCYCLYL COMPOUNDS AS PDE10 INHIBITORS | AMGEN INC. (US) | 2011-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306591-A1 | HETEROARYLOXYCARBOCYCLYL COMPOUNDS AS PDE10 INHIBITORS | PDE10A, PDE9A, HDAC10 | L3MBTL1 3881/4885DRD2 387/4885APLNR 3824/4885 |
| US-20160280703-A1 | Heteroaryloxycarbocyclyl Compounds as PDE 10 Inhibitors | PDE10A, PDE9A, PDE7A | L3MBTL1 3929/4885DRD2 412/4885APLNR 4010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.